Abstract
Bispecific antibodies can serve as mediators to retarget effector mechanisms to disease-associated sites. Studies over the past two decades have revealed the potentials but also the limitations of conventional bispecific antibodies. The development of recombinant antibody formats has opened up the possibility of generating bispecific molecules with improved properties. This review summarizes recent developments in the field of recombinant bispecific antibodies and discusses further requirements for clinical development.
Similar content being viewed by others
Article PDF
References
van Spriel AB, van Ojik HH, van de Winkel JGJ . Immunotherapeutic perspectives for bispecific antibodies. Immunol Today 2000; 21: 391–6.
Segal DM, Weiner GJ, Weiner LM . Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11: 558–62.
Hoogenboom HR, Chames P . Natural and designer binding sites made by phage display technology. Immunol Today 2000; 21: 371–8.
Brüggemann M, Taussig MJ . Production of human antibody repertoires in transgenic mice. Curr Opin Biotechnol 1997; 8: 455–8.
Ritter G, Cohen LS, Williams C, Richards EC, Old LJ, Welt S . Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res 2001; 61: 685–9.
Hellendoorn K, Jones T, Watkins J, Baker M, Hamilton A, Carr F . Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisationTM). Cancer Cell Int 2004; 4: S20.
Kufer P, Lutterbüse R, Baeuerle PA . A revival of bispecific antibodies. Trends Biotechnol 2004; 22: 238–44.
Kriangkum J, Xu B, Nagata LP, Fulton RE, Suresh MR . Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 2001; 18: 31–40.
Kontermann RE, Völkel T, Korn T . Production of recombinant bispecific antibodies. In: Antibody Engineering Protocols, 2nd edition-Methods in Molecular Biology Vol 51. Lo BKC (Ed). Totowa: Humana Press; 2003. p 227–42.
Ren-Heidenreich L, Davol PA, Douttab NM, Elfenbein GJ, Lum LG . Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overepressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 2004; 100: 1095–103.
Grosse-Hovest L, Müller S, Minoia R, Wolf E, Zakhartchenko V, Wenigerkind H, et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 2004; 101: 6858–63.
McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, et al. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 1999; 36: 433–45.
Brandaõ JG, Scheper RJ, Lougheed SM, Curiel DT, Tillman BW, Gerritsen WR, et al. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003; 21: 2268–72.
Kipriyanov SM, Moldenhauer G, Braunagel M, Reusch U, Cochlovius B, Le Gall F, et al. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies. J Mol Biol 2003; 330: 99–111.
Korn T, Nettelbeck DM, Völkel T, Müller R, Kontermann RE . Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 2004; 6: 642–51.
Holliger P, Prospero T, Winter G . “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90: 6444–8.
Lu D, Jimenez X, Witte L, Zhu Z . The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant bispecific diabody. Biochem Biophys Res Commun 2004; 318: 507–13.
Zhu Z, Presta LG, Zapata G, Carter P . Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6: 781–8.
Brüsselbach S, Korn T, Völkel T, Müller R, Kontermann RE . Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Targeting 1999; 4: 115–23.
Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, et al. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293: 41–56.
Völkel T, Korn T, Bach M, Müller R, Kontermann R . Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies. Protein Eng 2001; 14: 815–23.
Korn T, Müller R, Kontermann RE . Bispecific single-chain diabody-mediated killing of endoglin-expressing endothelial cells by cytotoxic T lymphocytes. J Immunother 2004; 27: 99–106.
Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, et al. High thermal stability is essential for tumor targeting of antibody fragments: engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res 1999; 59: 5758–67.
FitzGerald K, Holliger P, Winter G . Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 1997; 10: 1221–5.
Glockshuber R, Malia M, Pfitzinger I, Plückthun A . A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990; 29: 1362–7.
Le Gall F, Reusch U, Little M, Kipriyanov SM . Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17: 357–66.
Alt M, Müller R, Kontermann R . Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin g1 Fc or CH3 region. FEBS Lett 1999; 454: 90–4.
Lu D, Jimenez X, Zhang H, Atkins A, Brennan L, Balderes P, et al. Di-diabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Meth 2003; 279: 219–32.
Shahied LS, Tang Y, Alpaugh RK, Somer R, Greenspon D, Weiner LM . Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen-binding format. J Biol Chem 2004 Oct 7; [Epub ahead of print).
Cochlovius B, Kipriyanov SM, Stassar MKKG, Schuhmacher J, Benner A, Moldenhauer G, et al. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation. Cancer Res 2000; 60: 4336–41.
Harris JM, Chess RB . Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214–21.
Yang K, Basu A, Wang M, Chintala R, Hsieh MC, Liu S, et al.. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng 2003; 16: 761–70.
Bakker JM, Bleeker WK, Parren PWHI . Therapeutic antibody gene transfer: An active approach to passive immunity. Mol Ther 2004; 10: 411–6.
Kontermann RE, Korn T, Jérôme V . Recombinant adenoviruses for in vivo expression of antibody fragments. In: Recombinant antibody technology for cancer therapy: reviews and protocols. Welschof M, Krauss J (Eds). Methods in Molecular Medicine. Totowa: Humana Press; 2002. p 421–33.
Blanco B, Holliger P, Vile RG, Álvarez-Vallina L . Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J Immunol 2003; 171: 1070–7.
Kontermann RE, Müller R . Intracellular and cell surface displayed single-chain diabodies. J Immunol Meth 1999; 226: 179–88.
Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, et al. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem 2003; 278: 47812–9.
Weisbart RH, Wakelin R, Chan G, Miller CW, Koeffler PH . Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int J Oncol 2004; 25: 1113–8.
Augustin HG . Antiangiogenic tumour therapy: will it work? Trends Pharmacol Sci 1998; 19: 216–22.
Nettelbeck DM, Miller DW, Jerome V, Zuzarte M, Watkins SJ, Hawkins RE, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001; 3: 882–91.
Wüst T, Moosmayer D, Pfizenmaier K . Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J Biotechnol 2001; 92: 159–68.
Thorpe PE . Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415–27.
De Jonge J, Heirman C, De Veerman M, Van Meirvenne S, Moser M, Leo O, et al. In vivo retargeting of T cell effector function by recombinant bispecific single-chain Fv (anti-CD3 × anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. J Immunol 1998; 161: 1454–61.
Cochlovius B., Kipriyanov SM, Stassar MKKG, Christ O, Schuhmacher J, Strauß G, et al. Treatment of huma B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells. J Immunol 2000; 165: 888–95.
Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003; 170: 4397–402.
Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qianghua L, et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 × anti-CEA bispecific diabodies and B7 × anti-CEA bispecific fusion proteins. Cancer Res 1999; 59: 2909–16.
Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000; 15: 2098–103.
Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690–7.
Kipriyanov SM, Cochlovius, B, Schäfer HJ, Moldenhauer G, Bähre A, Le Gall F, et al. Synergistic antitumor effects of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of Non-Hodgkin's lymphoma. J Immunol 2002; 169: 137–44.
Schlenzka J, Moehler TM, Kipriyanov SM, Kornacker M, Benner A, Bähre A, et al. Combined effect of recombinant CC19 × CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drug 2004; 15: 915–9.
Löffler A, Gruen M, Wuchter C, Schriever F, Kufer P, Dreier T, et al. Leukemia 2003; 17: 900–9.
Gruen M, Bommert K, Bargou RC . T-cell-mediated lysis of B cells induced by a CD19 × CD3 bispecific single-chain antibody is perforin dependent and death receptor independent. Cancer Immunol Immunother 2004; 53: 625–32.
Kipriyanov SM, Moldenhauer G, Strauss G, Little M . Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int J Cancer 1998; 77: 763–72.
Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P . Biological properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3. J Immunol 1997; 158: 3965–70.
Maletz K, Kufer P, Mack M, Raum T, Pantel K, Riethmüller G, et al. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity. Int J Cancer 2001; 93: 409–16.
Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle PA, et al. Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody. Int J Cancer 2003; 105: 241–8.
Jost CR, Titus JA, Kurucz I, Segal DM . A single-chain bispecific Fv2 molecule produced in mammalian cells redirects lysis by activated CTL. Mol Immunol 1996; 33: 211–9.
Hayden MS, Linsley PS, Gayle MA, Bajorath J, Brady WA, Norris NA, et al. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol 1994; 1: 3–15.
Honemann D, Kufer P, Rimpler MM, Chatterjee M, Friedl S, Riecher F, et al. A novel recombinant bispecific single-chain antibody, bscWue-1 × CD3, induces T-cell-mediated cytotoxicity towards human multiple myeloma cells. Leukemia 2004; 18: 636–44.
Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, et al. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 2004; 125: 167–79.
McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielsen U, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001; 166: 6112–7.
Haisma HJ, Grill J, Curiel DT, Hoogeland S, van Beusechem VW, Pinedo HM, et al. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 2000; 7: 901–4.
Grill J, van Beusechem VW, van der Valk P, Dirven CMF, Leonhart A, Pherai DS, et al. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increased gene transfer into primary glioma cells and spheroids. Clin Cancer Res 2001; 7: 641–50.
Witlox MA, van Beusechem VW, Grill J, Haisma HJ, Schaap G, Bras J, et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med 2002; 4: 510–6.
Dirven CMF, Grill J, Lamfers MLM, van der Valk P, Leonhart AM, van Beusechem VW, et al. Gene therapy for meningioma: improved gene delivery with targeted adenoviruses. J Neurosurg 2002; 97: 441–9.
van Beusechem VW, Grill J, Mastenbroek DCJ, Wickham TJ, Roelvink PW, Haisma HJ, et al. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenovrial vectors with native tropism abolished. J Virol 2002; 76: 2753–62.
Heideman DA, van Beusechem VW, Offerhaus GJ, Wickham TJ, Roelvink PW, Craanen ME, et al. Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism. Hum Gene Ther 2002; 13: 1677–85.
Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G . Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 1996; 9: 299–305.
Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P . High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology 1996; 14: 192–6.
Helfrich W, Kroesen BJ, Roovers RC, Westers L, Molema G, Hoogenboom HR, et al. Construction and characterization of a bispecific diabody for retargeting T cells to human carcinomas. Int J Cancer 1998; 76: 232–9.
Krebs B, Griffin H, Winter G, Rose-John S . Recombinant human single chain Fv antibodies recognizing human interleukin-6. Specific targeting of cytokine-secreting cells. J Biol Chem 1998; 273: 2858–65.
Xiong D, Xu Y, Liu H, Peng H, Shao X, Lai Z, et al. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 × anti-CD3 bispecific diabody. Cancer Lett 2002; 177: 29–39.
Hayashi H, Asano R, Tsumoto K, katayose Y, Suzuki M, Unno M, et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunol Immunother 2004; 53: 497–509.
Takemura S, Kudo T, Asano R, Suzuki M, Tsumoto K, Sakurai N, et al. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol Immunother 2002; 51: 33–44.
Gao Y, Xiong D, Yang M, Liu H, Peng H, Shao X, et al. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein × anti-CD3 diabody. Leukemia 2004; 18: 513–20.
Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M . A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 1999; 94: 2562–8.
Kontermann RE, Wing MG, Winter G . Complement recruitment using bispecific diabodies. Nat Biotechnol 1997; 15: 629–31.
DeNardo SJ, DeNardo GL, DeNardo DG, Xiong CY, Shi XB, Winthrop MD, et al. Antibody phage libraries for the next generation of tumor targeting radioimmunotherapeutics. Clin Cancer Res 1999; 5: 3213s–3218s.
DeNardo DG, Xiong CY, Shi XB, DeNardo GL, DeNardo SJ . Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 2001; 16: 525–35.
Nettelbeck DM, Rivera AA, Kupsch J, Dieckmann D, Douglas JT, Kontermann RE, et al. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 2004; 108: 136–45.
Reusch U, Le Gall F, Hensel M, Moldenhauer G, Ho AD, Little M, et al. Effect of tetravalent bispecific CD19 × CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Cancer 2004; 112: 509.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kontermann, R. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26, 1–9 (2005). https://doi.org/10.1111/j.1745-7254.2005.00008.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2005.00008.x
Keywords
This article is cited by
-
Excellent removal of knob-into-hole bispecific antibody byproducts and impurities in a single-capture chromatography
Bioresources and Bioprocessing (2022)
-
Effective flow-through polishing strategies for knob-into-hole bispecific antibodies
Bioresources and Bioprocessing (2022)
-
A bispecific, crosslinking lectibody activates cytotoxic T cells and induces cancer cell death
Journal of Translational Medicine (2022)
-
Is the use of recombinant cGnRH may be a future alternative to control the fish spawning? Let us go with the goldfish example
Fish Physiology and Biochemistry (2021)
-
Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies
Cancer Immunology, Immunotherapy (2018)